01—Abstract
Summary
Summary of the 8-K filed January 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation (BSX) announced key executive leadership changes within its finance department, effective March 1, 2024.
Jonathan Monson, currently Senior Vice President, Global Controller and Chief Accounting Officer, will transition to the role of Senior Vice President, Investor Relations. This move signals a strengthened focus on investor communications and engagement. Concurrently, Emily Woodworth (Collins) has been appointed as the new Senior Vice President, Global Controller and Chief Accounting Officer.
Ms. Woodworth brings extensive experience within the company, having most recently served as Vice President of Finance and Controller for the Urology business. Her appointment to this critical financial role indicates a continuation of strong internal talent development and a commitment to experienced leadership within financial operations.
02—Key points
Key Highlights
- Jonathan Monson appointed Senior Vice President, Investor Relations, effective March 1, 2024.
- Monson will step down as Chief Accounting Officer on March 1, 2024.
- Emily Woodworth (Collins) appointed Senior Vice President, Global Controller and Chief Accounting Officer, effective March 1, 2024.
- Woodworth has a strong internal track record, including her recent role as VP of Finance and Controller for the Urology business.
- The appointments reflect internal promotions and a focus on continuity in financial leadership.
- Ms. Woodworth's compensation package will align with typical executive arrangements, including base salary, bonus, and stock awards.
03—Questions
Frequently Asked Questions
Why is Jonathan Monson moving to Investor Relations?
The filing indicates Mr. Monson's transition to Senior Vice President, Investor Relations, effective March 1, 2024. This move suggests a strategic decision by Boston Scientific to leverage his experience in financial leadership to enhance communication and engagement with the investment community.
What is Emily Woodworth's background?
Ms. Woodworth has a significant history within Boston Scientific, most recently serving as Vice President of Finance and Controller for the Urology business since July 2019. Prior to that, she held roles in Global Technical Accounting and External Reporting and served as Controller for the Cork, Ireland manufacturing plant and Neuromodulation business.
Will these changes impact the company's financial reporting or guidance?
The filing itself does not provide information on the direct impact on financial reporting or guidance. However, the appointment of an experienced internal candidate like Ms. Woodworth to the Chief Accounting Officer role suggests a commitment to maintaining strong financial controls and processes.
What are the key responsibilities of the new Chief Accounting Officer?
The Chief Accounting Officer is typically responsible for overseeing the company's accounting operations, financial reporting, internal controls, and compliance with accounting standards. Ms. Woodworth's appointment to this role indicates she will assume these critical functions for Boston Scientific.
04—Continue